FDA Clears Quidel C. difficile Assay for Life Tech's QuantStudio Dx and 7500 Fast Dx PCR Instruments | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared the Quidel Molecular Direct C. difficile Assay with Life Technologies' QuantStudio Dx and 7500 Fast Dx Applied Biosystems Real-Time PCR Instruments to be marketed in the US, the companies jointly announced today.

The assay kit includes an extraction-free, three-step sample preparation process requiring no heat step, timed step, or centrifugation. The fast and easy direct-to-amplification procedure allows for results in less than 70 minutes, Quidel and Life Tech said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.